The Massachusetts Biotechnology Council (MassBio) announced the release of its recent digital health report, Making Massachusetts a Leading Global Destination for Digital Health. The report, which was done by Deloitte, looks at the current state of the digital health industry in Massachusetts, challenges facing its growth, and opportunities the state has to lead.
The study also identified at least three key opportunities where Massachusetts stakeholders could invest time and resources to drive growth and differentiation of its digital health ecosystem These include, but are not limited to: fostering better access to data and patients; developing a workforce that is able to tackle complex healthcare challenges through digital technology; and better coordinating the digital health entrepreneur and investor ecosystems. In addition to advocating for what the state can do, MassBio plans to launch new initiatives to support digital health entrepreneurs.
To read or download the full report, visit here.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.